Cbay stock forecast.

Nov 3, 2023 · Cymabay Therapeutics Inc (NASDAQ:CBAY) trade information. Cymabay Therapeutics Inc (CBAY) has traded red over the past five days. The stock hit a weekly high of 16.87 this Thursday, 11/02/23. The 5-day price performance for the stock is 8.04%, and 17.06% over 30 days. With these gigs, the year-to-date price performance is 161.56%.

Cbay stock forecast. Things To Know About Cbay stock forecast.

According to analyst projections, CBAY’s forecast low is $20.00 with $34.00 as the target high. To hit the forecast high, the stock’s price needs a -82.21% plunge from its current level, while the stock would need to soar -7.18% for it to hit the projected low. Cymabay Therapeutics Inc (CBAY) estimates and forecastsThe current CymaBay Therapeutics [ CBAY] share price is $17.90. The Score for CBAY is 74, which is 48% above its historic median score of 50, and infers lower risk than normal. CBAY is currently trading in the 70-80% percentile range relative to its historical Stock Score levels.Stock Price Forecast. The 1 analysts offering 12-month price forecasts for Swvl Holdings Corp have a median target of 37.50, with a high estimate of 37.50 and a low estimate of 37.50. The median ...The 12 analysts offering 1 year price forecasts for CBAY have a max estimate of — and a min estimate of —. Analyst rating Based on 13 analysts giving stock ratings to CBAY in the past 3 months.Find real-time IBM - International Business Machines Corp stock quotes, company profile, news and forecasts from CNN Business.

Over the past 3 months, 14 analysts have published their opinion on CymaBay Therapeutics (NASDAQ:CBAY) stock. These analysts are typically employed by large Wall Street banks and tasked with ...

View the latest CymaBay Therapeutics Inc. (CBAY) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Their ZOM share price targets range from $6.00 to $6.00. On average, they expect the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 3,421.1% from the stock's current price. View analysts price targets for ZOM or view top-rated stocks among Wall Street analysts.(See CBAY stock forecast) Cerevel Therapeutics . The next Edelman choice is Cerevel, a company established in 2018 that specializes in the field of neuroscience. Cerevel’s focus is on the ...Cymabay Therapeu share price live 15.260, this page displays NASDAQ CBAY stock exchange data. View the CBAY premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Cymabay Therapeu real time stock price chart below. ... {erl-102889||earnings that beat analysts' …Village Farms International Inc () Stock Market info Recommendations: Buy or sell Village Farms International stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Village Farms International share forecasts, stock quote and buy / sell signals below.According to present data Village Farms International's VFF shares and …

Nov 24, 2023 · Stock analysis for Cymabay Therapeutics Inc (CBAY:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

CDTX Stock 12 Months Forecast. Based on 1 Wall Street analysts offering 12 month price targets for Cidara Therapeutics in the last 3 months. The average price target is $6.00 with a high forecast of $6.00 and a low forecast of $6.00. The average price target represents a 679.22% change from the last price of $0.77.

provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their research and their ... CBH one year forecast. AllianzGI Convertible & Income 2024 Target Term Fund stock monthly and weekly forecasts. Skip to content. FORECST.COM 2023 – 2026 Stock Market Forecast CBH stock forecast for 2023 – 2027. Last updated: December 2, 2023. Are you interested in AllianzGI Convertible & Income 2024 Target Term Fund …Analyst Forecast. According to 12 analysts, the average rating for CBAY stock is "Strong Buy." The 12-month stock price …Stock Price Forecast The 9 analysts offering 12-month price forecasts for Blink Charging Co have a median target of 5.00, with a high estimate of 25.00 and a low estimate of 3.00.All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange ...Stock Price Forecast. The 10 analysts offering 12-month price forecasts for Crescent Point Energy Corp have a median target of 10.24, with a high estimate of 13.84 and a low estimate of 8.78. The ...With stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.

Forecast . Price target. 24.08 0.00 0.00%. The 12 analysts offering 1 year price forecasts for CBAY have a max estimate of — and a min estimate of —. Analyst rating. Based on 13 analysts giving stock ratings to CBAY in the past 3 months. EPS. Annual Annual Quarterly Quarterly More MoreOver the past 3 months, 14 analysts have published their opinion on CymaBay Therapeutics CBAY stock. These analysts are typically employed by large Wall Street banks and tasked with understanding ...Stock Price Forecast The 6 analysts offering 12-month price forecasts for Aldeyra Therapeutics Inc have a median target of 9.00, with a high estimate of 11.00 and a low estimate of 7.00.Xenon Pharmaceuticals Inc. 28.97. +0.24. +0.84%. Get CymaBay Therapeutics Inc (CBAY:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.After registering a 6.31% upside in the last session, Cymabay Therapeutics Inc (CBAY) has traded red over the past five days. The stock hit a weekly high of 19.10 this Friday, 11/24/23, jumping 6.31% in its intraday price action. The 5-day price performance for the stock is 4.62%, and 26.28% over 30 days. With these gigs, the year-to-date price ...

Nov 24, 2023 · A high-level overview of CymaBay Therapeutics, Inc. (CBAY) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.

Of course, the risk is real, too; not every penny stock is going to show th Risk and reward are the yin and yang of stock trading, the two opposite but essential ingredients in every market success.CBAY stock showed promising performance on November 8, 2023, according to data from CNN Money. The 12 analysts offering 12-month price forecasts for CymaBay Therapeutics Inc had a median target of 22.50, with a high estimate of 33.00 and a low estimate of 19.00.EBAY Regular Dividend: EBAY will begin trading ex-dividend today with a $0.25 dividend payable to shareholders of record as of 12/01/23. Quote. Profile. News. Charts. Forecasts. Financials ...CBAY Signals & Forecast. Mostly positive signals in the chart today. The Cymabay Therapeutics Inc stock holds buy signals from both short and long-term Moving Averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average.The current average CBAY price target, as estimated by these analysts, is $0.00. The predictions for the future CBAY stock price range from a low of $0.00 to a high of $0.00, highlighting the variability of market expectations for CBAY. CBAY stock showed promising performance on November 8, 2023, according to data from CNN Money. The 12 analysts offering 12-month price forecasts for CymaBay Therapeutics Inc had a median target of 22.50, with a high estimate of 33.00 and a low estimate of 19.00.According to . 9 Wall Street analysts that have issued a 1 year CBAY price target, the average CBAY price target is $24.56, with the highest CBAY stock price forecast at $34.00 and the lowest CBAY stock price forecast at $15.00.Nov 21, 2023 · According to analyst projections, CBAY’s forecast low is $20.00 with $34.00 as the target high. To hit the forecast high, the stock’s price needs a -82.21% plunge from its current level, while the stock would need to soar -7.18% for it to hit the projected low. Cymabay Therapeutics Inc (CBAY) estimates and forecasts Dec 1, 2023 · 6 analysts have issued 12 month price objectives for Spruce Biosciences' shares. Their SPRB share price targets range from $4.00 to $10.00. On average, they expect the company's share price to reach $7.67 in the next year. This suggests a possible upside of 463.7% from the stock's current price. provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their research and their ...

3 Wall Street analysts have issued twelve-month target prices for Aldeyra Therapeutics' shares. Their ALDX share price targets range from $8.00 to $15.00. On average, they expect the company's share price to reach $12.33 in the next year. This suggests a possible upside of 370.7% from the stock's current price.

What happened. Shares of CymaBay Therapeutics ( CBAY 4.87%) were up more than 37% as of 11:15 a.m. ET on Friday. The clinical-stage biotech saw its shares rise after Ipsen and Genfit announced ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life. Track Cymabay Therapeutics Inc (CBAY) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors. Join the Conversation! Build your trading network; Follow your favorite assets ...Based on 10 Wall Street analysts offering 12 month price targets for CymaBay Therapeutics in the last 3 months. The average price target is $24.40 with a high forecast of $33.00 and a low forecast of $20.00. The average price target represents a 29.93% change from the last price of $18.78. Highest Price Target $33.00. Average Price Target $24.40. Analysts Offer Insights on Healthcare Companies: CymaBay Therapeutics (CBAY), Mersana Therapeutics (MRSN) and Verona Pharma (VRNA) November 8, 2023 TipRanks.Based on analysts offering 12 month price targets for CBAY in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 .Cymabay Therapeutics (CBAY) Company Description. CymaBay Therapeutics Inc is a clinical-stage biopharmaceutical company. Its main business involves the development of therapeutics such as Arhalofenate, MBX-8025, and MBX-2982. These drugs are intended to treat serious metabolic disorders. Arhalofenate is used to treat gout, MBX-2982 is an oral ...Based on short-term price targets offered by 11 analysts, the average price target for CymaBay Therapeutics Inc. comes to $24.45. The forecasts range from a low of $20.00 to a high of $34.00.16 Wall Street analysts have issued 12 month price targets for Exelixis' stock. Their EXEL share price targets range from $18.00 to $32.00. On average, they anticipate the company's stock price to reach $25.44 in the next twelve months. This suggests a possible upside of 18.3% from the stock's current price. View analysts price …CymaBay Therapeutics Stock Forecast and Price Target. If CymaBay Therapeutics's stock price reached the average yearlong target of $10.00 given by five well-known analysts in recent months, there would be a potential downside of approximately -18.57% from its last closing price in July, 2023.CymaBay Therapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of proprietary new medicines for important human diseases. The Company's lead ...

At the close of trading, the stock’s price was $2.30, to imply a decrease of -3.77% or -$0.09 in intraday trading. The ATUS share’s 52-week high remains $5.57, putting it -142.17% down since that peak but still an impressive 12.61% since price per share fell to its 52-week low of $2.01.Are you tired of spending countless hours manually tracking your inventory? Are you looking for a way to improve your decision making and forecasting processes? Look no further than a free inventory tracking template.Wall Street Stock Market & Finance report, prediction for the future: You'll find the CBAK Energy Technology share forecasts, stock quote and buy / sell signals below. According to present data CBAK Energy Technology's CBAT shares and potentially its market environment have been in bearish cycle last 12 months (if exists).Instagram:https://instagram. vbtlx dividendqenc stockdeckers outdoor shoesrad investments reviews 41 Wall Street research analysts have issued 12-month target prices for Shopify's shares. Their SHOP share price targets range from $41.00 to $82.00. On average, they predict the company's share price to reach $65.09 in the next twelve months. This suggests that the stock has a possible downside of 8.3%.Weather forecasting plays a crucial role in our daily lives, helping us plan our activities and make informed decisions. But have you ever wondered how meteorologists are able to accurately predict the weather? One of the key components in ... virtual reality companies stockspy stock resistance Cymabay Therapeutics Inc (NASDAQ:CBAY) trade information. Cymabay Therapeutics Inc (CBAY) has traded red over the past five days. The stock hit a weekly high of 16.87 this Thursday, 11/02/23. The 5-day price performance for the stock is 8.04%, and 17.06% over 30 days. With these gigs, the year-to-date price performance is 161.56%.Nov 27, 2023 · See the latest CymaBay Therapeutics Inc stock price (CBAY:XNAS), related news, valuation, dividends and more to help you make your investing decisions. wellesley income fund vanguard EBAY Regular Dividend: EBAY will begin trading ex-dividend today with a $0.25 dividend payable to shareholders of record as of 12/01/23. Quote. Profile. News. Charts. Forecasts. Financials ...ACIU Stock 12 Months Forecast. Based on 2 Wall Street analysts offering 12 month price targets for AC Immune SA in the last 3 months. The average price target is $16.00 with a high forecast of $16.00 and a low forecast of $16.00. The average price target represents a 417.80% change from the last price of $3.09.